170 related articles for article (PubMed ID: 31689794)
1. Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.
Lee SW; Lee TY; Peng YC; Yang SS; Yeh HZ; Chang CS
Medicine (Baltimore); 2019 Nov; 98(44):e17692. PubMed ID: 31689794
[TBL] [Abstract][Full Text] [Related]
2. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
3. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice.
Giannini EG; Bucci L; Garuti F; Brunacci M; Lenzi B; Valente M; Caturelli E; Cabibbo G; Piscaglia F; Virdone R; Felder M; Ciccarese F; Foschi FG; Sacco R; Svegliati Baroni G; Farinati F; Rapaccini GL; Olivani A; Gasbarrini A; Di Marco M; Morisco F; Zoli M; Masotto A; Borzio F; Benvegnù L; Marra F; Colecchia A; Nardone G; Bernardi M; Trevisani F;
Hepatology; 2018 May; 67(5):1784-1796. PubMed ID: 29159910
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Sohn W; Paik YH; Cho JY; Lim HY; Ahn JM; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
J Hepatol; 2015 May; 62(5):1112-21. PubMed ID: 25514557
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Bruix J; Cheng AL; Meinhardt G; Nakajima K; De Sanctis Y; Llovet J
J Hepatol; 2017 Nov; 67(5):999-1008. PubMed ID: 28687477
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study.
Lee YC; Wang JH; Chen CH; Hung CH; Lo KC; Yen YH; Kee KM; Hu TH; Lu SN; Kuo YH
Kaohsiung J Med Sci; 2021 Oct; 37(10):894-902. PubMed ID: 34166565
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma.
Lee SW; Lee TY; Peng YC; Yang SS; Yeh HZ; Chang CS
J Dig Dis; 2020 May; 21(5):287-292. PubMed ID: 32315498
[TBL] [Abstract][Full Text] [Related]
10. Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West.
Yen YH; Cheng YF; Wang JH; Lin CC; Chen YY; Yong CC; Liu YW; Cheng JY; Chen CH; Hu TH
PLoS One; 2020; 15(3):e0230005. PubMed ID: 32163475
[TBL] [Abstract][Full Text] [Related]
11. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
Hsu PY; Hsu CT; Yeh ML; Huang CF; Huang CI; Liang PC; Lin YH; Hsieh MY; Wei YJ; Hsieh MH; Dai CY; Lin ZY; Chen SC; Huang JF; Yu ML; Chuang WL
Dig Dis Sci; 2020 Jul; 65(7):2120-2129. PubMed ID: 31722058
[TBL] [Abstract][Full Text] [Related]
12. A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015.
Huang CC; Chen HY; Chang RH; Liao PA; Lien HH; Hung CS; Yang SS; Hu JT
Drug Des Devel Ther; 2019; 13():397-404. PubMed ID: 30774305
[TBL] [Abstract][Full Text] [Related]
13. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Xu L; Gao H; Huang J; Wang H; Zhou Z; Zhang Y; Li S; Chen M
J Gastroenterol Hepatol; 2015 Jun; 30(6):1032-9. PubMed ID: 25639513
[TBL] [Abstract][Full Text] [Related]
14. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
15. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
[TBL] [Abstract][Full Text] [Related]
16. Impact of skeletal muscle volume on patients with BCLC stage-B hepatocellular carcinoma undergoing sorafenib therapy.
Saeki I; Yamasaki T; Yamauchi Y; Kawaoka T; Uchikawa S; Hiramatsu A; Aikata H; Kobayashi K; Kondo T; Ogasawara S; Chiba T; Kawano R; Chayama K; Kato N; Takami T
Cancer Med; 2023 May; 12(9):10625-10635. PubMed ID: 36951579
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
Yau T; Hsu C; Kim TY; Choo SP; Kang YK; Hou MM; Numata K; Yeo W; Chopra A; Ikeda M; Kuromatsu R; Moriguchi M; Chao Y; Zhao H; Anderson J; Cruz CD; Kudo M
J Hepatol; 2019 Sep; 71(3):543-552. PubMed ID: 31176752
[TBL] [Abstract][Full Text] [Related]
18. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
[TBL] [Abstract][Full Text] [Related]
19. Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study.
Zhang Y; Fan W; Wang Y; Huang G; Li J
Cancer Control; 2019; 26(1):1073274819872216. PubMed ID: 31466465
[TBL] [Abstract][Full Text] [Related]
20. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area.
Shim JH; Park JW; Choi JI; Park BJ; Kim CM
J Cancer Res Clin Oncol; 2009 Apr; 135(4):617-25. PubMed ID: 18846384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
